ERBB2 and breast carcinoma: In particular, human epidermal growth factor receptor 2-positive (HER2+) breast cancers and squamous cell lung cancers showed positive rates of 16.0% (four out of 25 cases) and 14.6% (seven out of 48 cases), respectively, which were significantly higher than the average (Fisher’s exact test, P < 0.003 and P < 0.001, respectively).